Radotinib as 3rd or Later Line Therapy in CP-CML
The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.
Chronic Myeloid Leukemia
DRUG: Radotinib
Rate of Major cytogenetic response, The rate of achieving major cytogenetic response \[35% or less t(9;22) chromosome by conventional banding technique\] in bone marrow by 12 months after radotinib treatment will be the primary end point., by 12 months after radotinib treatment
Rate of Major Molecular response (MR3.0) on each time point, up to 12 months|The number of Participants with Adverse Events, 12 months
The purpose of this study is to determine whether radotinib 400mg bid is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors. The primary end point is major cytogenetic response by 12 months.